期刊文献+

紫杉醇联合卡铂不同给药途径治疗卵巢癌52例疗效分析 被引量:6

下载PDF
导出
摘要 目的比较紫杉醇联合卡铂不同给药途径治疗卵巢癌患者的临床效果和安全性。方法 104例卵巢癌患者随机分为对照组和观察组,各52例。对照组患者采用静脉给药,观察组患者采用腹腔灌注给药。每3周为1个疗程,比较治疗3个疗程后两组患者的临床效果和不良反应发生情况。结果观察组患者总有效率80.8%明显高于对照组61.5%,差异有统计学意义(χ2=5.926,P=0.038)。观察组患者骨髓抑制发生率明显低于对照组,而胃肠道反应、肝肾毒性和关节肌肉痛明显高于对照组,差异均有统计学意义(P<0.05)。结论紫杉醇联合卡铂腹腔灌注给药治疗卵巢癌患者临床效果优于静脉给药,骨髓抑制发生率小,但要注意其他不良反应,是一种值得推广应用的给药方法。
作者 于俊丽
出处 《中国现代药物应用》 2015年第3期134-135,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献4

二级参考文献26

  • 1闫长会,施畅,李玉凤,廖明阳.新铂类药物双环铂与顺铂、卡铂体内毒性的比较研究[J].中国新药杂志,2005,14(10):1156-1159. 被引量:18
  • 2Sandercock J,Parmar MK,Torri V,et al.First-line treatment for advanced ovarian cancer:paclitaxel,platinum and the evidence[J].Br J Cancer,2002,87(8):815-824.
  • 3Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanopaicle extravasation from tumor vaseulature [ J ]. Caneer Res, 2001,61 ( 7 ) : 3027 -3032.
  • 4Nicoletto MO,Padrini R, Galeotti F,et al. Pharmacoki- netics of intraperitoncal hyerlhermic perfusion with mi- toxantrone in ovarian Cancer Chemolher Pharmaeol, 2000,45 ( 6 ) : 457-462.
  • 5Portilla AG, Surgarbaker PH, Chang D. Second look sur gery after eytore duction and intraperifoneal cancer-a nalysis of progonostic features [ J ]. World J Surg, 1999 23( 1 ) :23-29.
  • 6柳英兰,韩旭,徐柏,郑建华.含紫杉醇类和卡铂的不同方案治疗卵巢癌临床分析[J].现代肿瘤医学,2007,15(12):1831-1833. 被引量:5
  • 7Sjóvall K,Nilsson B,Einhorn N.The significance of serum CA125elevationin malignant and nonmalignant diseases. Gynecologic Oncology . 2002
  • 8Huhtinen K,Suvitie P,Hiissa J,et al.Serum HE4concen-tration differentiates malignant ovarian tumours fromovarian endometriotic cysts. British Journal of Cancer . 2009
  • 9Moore RG,Mc Meekin DS,Brown AK,et al.Anovel multi-ple marker bioassay utilizing HE4and CA125for the predic-tion of ovarian cancer in patients with a pelvicmass. Gynecologic Oncology . 2009
  • 10Yurkovetsky Z,Skates S,Lomakin A,et al.Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology . 2010

共引文献46

同被引文献122

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2Georg Fluegen,Frank Jankowiak,Luisa Zacarias Foehrding,Feride Kroepil,Wolfram T Knoefel,Stefan A Topp.Intrahepatic endometriosis as differential diagnosis: Case report and literature review[J].World Journal of Gastroenterology,2013,19(29):4818-4822. 被引量:9
  • 3郑毅.紫杉醇对顺铂耐药卵巢癌细胞的影响[J].齐齐哈尔医学院学报,2007,28(11):1320-1321. 被引量:6
  • 4Hoff PM,Saad ED,Costa F,et al. Literature review and practical aspects on the management of Lobaplatin-associ- ated toxicity [J]. Clin Colorectal Cancer,2012,11 (2) :93- 100.
  • 5Edwards IR,Aronson JK. Adverse drug reactions:definitions, diagnosis,and management [J]. The Lancet,2000,356(8237) : 1255-1259.
  • 6Edeline J, Boucher E, Rolland Y, et al. Comparison of tu- mor response by response evaluation criteria in solid tu- mors (RECIST) and modified RECIST in patients treated with sorafeoib for hepatocellular carcinoma [J]. Cancer, 2012,118(1) : 147-156.
  • 7Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus Paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7):a randomised, multicentre,open,label,phase 3 trial [J]. Lancet Oncol, 2014,15(4) :396--405.
  • 8Pignata S,Seambia G, Ferrandina G,et al. Carboplatin plus Paclitaxel versus Carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovar- ian cancer:the MITO-2 randomized phase Ⅲ trial [J]. J Clin Oncol, 2011,29(27) : 3628-3635.
  • 9Dalton HJ,Yu X,Hu L,et al. An economic analysis of dose dense weekly Paclitaxel plus Carboplatin versus ev- ery-3-week Paclitaxel plus Carboplatin in the treatment of advanced ovarian cancer [J]. Gynecol Oncol,2012,124 (2) : 199-204.
  • 10Steffensen KD,Waldstrom M,Jakobsen A. The relation- ship of platinum resistance and ERCC1 protein expres- sion in epithelial ovarian cancer [J]. Int J Gynecol Can- cer,2009, 19(5) : 820-825.

引证文献6

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部